DE60131967D1 - Nr1h4-kern-rezeptor-bindende verbindungen - Google Patents
Nr1h4-kern-rezeptor-bindende verbindungenInfo
- Publication number
- DE60131967D1 DE60131967D1 DE60131967T DE60131967T DE60131967D1 DE 60131967 D1 DE60131967 D1 DE 60131967D1 DE 60131967 T DE60131967 T DE 60131967T DE 60131967 T DE60131967 T DE 60131967T DE 60131967 D1 DE60131967 D1 DE 60131967D1
- Authority
- DE
- Germany
- Prior art keywords
- nuclear receptor
- receptor binding
- binding compounds
- nr1h4
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/11—Compounds covalently bound to a solid support
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01119473A EP1285914B1 (de) | 2001-08-13 | 2001-08-13 | Nr1h4-kern-rezeptor-bindende verbindungen |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60131967D1 true DE60131967D1 (de) | 2008-01-31 |
Family
ID=8178316
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60131967T Expired - Lifetime DE60131967D1 (de) | 2001-08-13 | 2001-08-13 | Nr1h4-kern-rezeptor-bindende verbindungen |
Country Status (5)
Country | Link |
---|---|
US (3) | US6974830B2 (de) |
EP (3) | EP1285914B1 (de) |
AT (1) | ATE381542T1 (de) |
DE (1) | DE60131967D1 (de) |
WO (2) | WO2003016288A1 (de) |
Families Citing this family (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1392714T3 (da) | 2001-03-12 | 2006-01-09 | Intercept Pharmaceuticals Inc | Steroider som agonister for FXR |
US6987121B2 (en) | 2002-04-25 | 2006-01-17 | Smithkline Beecham Corporation | Compositions and methods for hepatoprotection and treatment of cholestasis |
US20060148858A1 (en) * | 2002-05-24 | 2006-07-06 | Tsuyoshi Maekawa | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity |
EP1562915A1 (de) * | 2002-11-22 | 2005-08-17 | SmithKline Beecham Corporation | Farnesoid x rezeptor agonisten |
CA2540364A1 (en) * | 2003-09-26 | 2005-04-07 | Forbes Medi-Tech Inc. | Method of inhibiting the expression of a multi-drug resistance genes and inhibiting the production of proteins resulting from the expression of such genes thereby enhancing the effectiveness of chemotherapeutic agents to treat cancers |
WO2005042692A2 (en) * | 2003-10-31 | 2005-05-12 | Forbes Medi-Tech Inc. | A method of inhibiting the expression of genes which mediate cellular cholesterol influx in animal cells and inhibiting the production of proteins resulting from the expression of such genes using cholesterol absorption inhibitors |
WO2005051298A2 (en) | 2003-11-19 | 2005-06-09 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing thyromimetics |
EP3002283B1 (de) | 2003-12-26 | 2017-06-14 | Kyowa Hakko Kirin Co., Ltd. | Thiazol-derivate |
EP2712617B2 (de) | 2004-03-12 | 2020-11-18 | Intercept Pharmaceuticals, Inc. | Behandlung Von Fibrose Mit Fxr-Liganden |
US10987362B2 (en) | 2004-03-12 | 2021-04-27 | Intercept Pharmaceuticals, Inc. | Treatment of fibrosis using FXR ligands |
US20060019907A1 (en) * | 2004-07-12 | 2006-01-26 | Research Development Foundation | Guggulsterone: an inhibitor of nuclear factor - kappaB and IkappaBalpha kinase activation and uses thereof |
PT1773768T (pt) | 2004-07-30 | 2018-11-30 | Exelixis Inc | Derivados de pirrol como agentes farmacêuticos |
WO2006029719A2 (en) * | 2004-09-14 | 2006-03-23 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with nuclear receptor subfamily 1, group h, member 4 (nr1h4) |
US20060252670A1 (en) * | 2004-10-14 | 2006-11-09 | Intercept Pharmaceuticals Inc. | Method of reducing drug-induced adverse side effects in a patient |
ITMI20050912A1 (it) * | 2005-05-19 | 2006-11-20 | Erregierre Spa | Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici |
CA2606499C (en) | 2005-05-26 | 2017-06-13 | Metabasis Therapeutics, Inc. | Thyromimetics for the treatment of fatty liver diseases |
US7618956B2 (en) * | 2005-05-31 | 2009-11-17 | The Gillette Company | Reduction of hair growth |
WO2007052843A1 (ja) * | 2005-11-04 | 2007-05-10 | Takeda Pharmaceutical Company Limited | 複素環アミド化合物およびその用途 |
EP1962838B1 (de) | 2005-12-19 | 2011-09-28 | GlaxoSmithKline LLC | Farnesoid-x-rezeptor-agonisten |
CN101374834B (zh) | 2006-02-03 | 2011-12-14 | 伊莱利利公司 | 用于调节fxr的化合物和方法 |
PL2029547T3 (pl) | 2006-05-24 | 2010-09-30 | Lilly Co Eli | Agoniści FXR |
JP5225984B2 (ja) * | 2006-05-24 | 2013-07-03 | イーライ リリー アンド カンパニー | Fxrを調節する化合物及び方法 |
EP1886685A1 (de) | 2006-08-11 | 2008-02-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methoden, Verwendungen und Zusammensetzungen zur Modulation der Replikation von HCV durch Aktivierung oder Hemmung des Farnesoid X Rezeptors |
EP1894928A1 (de) | 2006-08-29 | 2008-03-05 | PheneX Pharmaceuticals AG | Fxr bindende heterocyclische verbindungen |
EP1894924A1 (de) * | 2006-08-29 | 2008-03-05 | Phenex Pharmaceuticals AG | Heterozyklische FXR Bindungsverbindungen |
CL2007003035A1 (es) * | 2006-10-24 | 2008-05-16 | Smithkline Beechman Corp | Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos, |
JP5292310B2 (ja) | 2007-01-19 | 2013-09-18 | インターセプト ファーマシューティカルズ, インコーポレイテッド | Tgr5調節剤としての23−置換胆汁酸およびその使用方法 |
WO2009005998A1 (en) * | 2007-07-02 | 2009-01-08 | Smithkline Beecham Corporation | Farnesoid x receptor agonists |
TW200906823A (en) | 2007-07-16 | 2009-02-16 | Lilly Co Eli | Compounds and methods for modulating FXR |
AU2008333320B2 (en) | 2007-12-04 | 2012-12-20 | F. Hoffmann-La Roche Ag | Isoxazolo-pyrazine derivatives |
US7902201B2 (en) | 2007-12-04 | 2011-03-08 | Hoffmann-La Roche Inc. | Isoxazolo-pyrazine derivatives |
US7943619B2 (en) | 2007-12-04 | 2011-05-17 | Hoffmann-La Roche Inc. | Isoxazolo-pyridazine derivatives |
EP2128158A1 (de) | 2008-05-26 | 2009-12-02 | Phenex Pharmaceuticals AG | Heterocyclische Cyclopropyl-substituierte FXR-bindende Verbindungen |
CN105037476B (zh) | 2008-07-30 | 2018-06-12 | 英特塞普特医药品公司 | Tgr5调节剂及其使用方法 |
KR20110082145A (ko) * | 2008-10-21 | 2011-07-18 | 메타볼렉스, 인코포레이티드 | 아릴 gpr120 수용체 작동약 및 이의 용도 |
HUE039171T2 (hu) | 2008-11-19 | 2018-12-28 | Intercept Pharmaceuticals Inc | TGR5 modulátorok és azok alkalmazási eljárása |
US20110257139A1 (en) | 2008-12-19 | 2011-10-20 | Royal College Of Surgeons In Ireland | Treatment of diarrhoea |
TW201033201A (en) | 2009-02-19 | 2010-09-16 | Hoffmann La Roche | Isoxazole-isoxazole and isoxazole-isothiazole derivatives |
US8389550B2 (en) | 2009-02-25 | 2013-03-05 | Hoffmann-La Roche Inc. | Isoxazoles / O-pyridines with ethyl and ethenyl linker |
US8222246B2 (en) | 2009-04-02 | 2012-07-17 | Hoffmann-La Roche Inc. | Substituted isoxazoles |
US20100280019A1 (en) | 2009-04-30 | 2010-11-04 | Roland Jakob-Roetne | Isoxazoles |
KR101701533B1 (ko) | 2009-05-05 | 2017-02-13 | 에프. 호프만-라 로슈 아게 | 아이속사졸-피리다진 유도체 |
KR101354335B1 (ko) | 2009-05-05 | 2014-02-19 | 에프. 호프만-라 로슈 아게 | 인지 장애의 치료에 사용되는 gaba a 수용체 역 작용제로서의 아이속사졸-티아졸 유도체 |
KR101384829B1 (ko) | 2009-05-05 | 2014-04-15 | 에프. 호프만-라 로슈 아게 | 이속사졸-피라졸 유도체 |
CN102414206B (zh) | 2009-05-05 | 2014-11-05 | 霍夫曼-拉罗奇有限公司 | 异*唑-吡啶衍生物 |
WO2010127978A1 (en) | 2009-05-07 | 2010-11-11 | F. Hoffmann-La Roche Ag | Isoxazole-pyridine derivatives as gaba modulators |
EP2289883A1 (de) | 2009-08-19 | 2011-03-02 | Phenex Pharmaceuticals AG | Neue Aktivitätsmodulationsverbindungen für FXR- (NR1H4) |
EP2545964A1 (de) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Neuartige FXR- (NR1H4)-Binde- und -Aktivitätsmodulationsverbindungen |
WO2013037482A1 (en) | 2011-09-15 | 2013-03-21 | Phenex Pharmaceuticals Ag | Farnesoid x receptor agonists for cancer treatment and prevention |
US8785435B2 (en) | 2011-10-20 | 2014-07-22 | Hoffmann-La Roche Inc. | Solid forms |
US9982008B2 (en) | 2012-06-19 | 2018-05-29 | Intercept Pharmaceuticals, Inc. | Preparation and uses of obeticholic acid |
CA3028207A1 (en) | 2012-06-19 | 2013-12-27 | Intercept Pharmaceuticals, Inc. | Preparation, uses and solid forms of obeticholic acid |
BR112016005507B1 (pt) | 2013-09-11 | 2023-02-07 | Centre National De La Recherche Scientifique (Cnrs) | Uso de um agonista do receptor farnesoide x (fxr) |
EP3006939A1 (de) | 2014-10-06 | 2016-04-13 | Gilead Sciences, Inc. | Histidinreiches Glycoprotein als Marker zur hepatischen Farnesoid-X-Aktivierung |
US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
EP3034501A1 (de) | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Hydroxyhaltige FXR (NR1H4) modulierende Verbindungen |
EP3034499A1 (de) | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Neuartige FXR (NR1H4) modulierende Verbindungen |
AR103624A1 (es) | 2015-02-06 | 2017-05-24 | Intercept Pharmaceuticals Inc | Composiciones farmacéuticas para terapia de combinación |
TWI698430B (zh) | 2015-02-13 | 2020-07-11 | 南北兄弟藥業投資有限公司 | 三環化合物及其在藥物中的應用 |
CA2981503C (en) | 2015-03-31 | 2023-09-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
KR20170132879A (ko) | 2015-04-07 | 2017-12-04 | 인터셉트 파마슈티컬즈, 인크. | 조합 요법을 위한 약제학적 조성물 |
WO2017189663A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
US10080742B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
US10080741B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
US10144729B2 (en) | 2016-05-18 | 2018-12-04 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as FXR agonists and methods of use thereof |
WO2017201155A1 (en) | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF |
WO2017201152A1 (en) | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
JP6678779B2 (ja) | 2016-06-13 | 2020-04-08 | ギリアード サイエンシーズ, インコーポレイテッド | Fxr(nr1h4)調節化合物 |
CA2968836A1 (en) | 2016-06-13 | 2017-12-13 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
TW201808283A (zh) | 2016-08-05 | 2018-03-16 | 廣東東陽光藥業有限公司 | 含氮三環化合物及其在藥物中的應用 |
KR20190056436A (ko) | 2016-10-04 | 2019-05-24 | 이난타 파마슈티칼스, 인코포레이티드 | Fxr 작용제로서의 이속사졸 유사체 및 그의 사용 방법 |
US10597391B2 (en) | 2016-10-26 | 2020-03-24 | Enanta Pharmaceuticals, Inc. | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof |
KR20190104524A (ko) | 2016-11-21 | 2019-09-10 | 바이킹 테라퓨틱스 인코포레이티드 | 당원축적질환의 치료 방법 |
AU2018243719B2 (en) | 2017-03-28 | 2021-01-21 | Gilead Sciences, Inc. | Therapeutic combinations for treating liver diseases |
CN110944635A (zh) | 2017-03-30 | 2020-03-31 | 国家医疗保健研究所 | 用于减少附加体病毒的持久性和表达的方法和药物组合物 |
BR112019021320A2 (pt) | 2017-04-12 | 2020-05-19 | Il Dong Pharma | composto e composição farmacêutica |
KR102600115B1 (ko) | 2017-06-05 | 2023-11-09 | 바이킹 테라퓨틱스 인코포레이티드 | 섬유증 치료를 위한 조성물 |
ES2944601T3 (es) | 2017-11-01 | 2023-06-22 | Bristol Myers Squibb Co | Compuestos multicíclicos como moduladores del receptor farnesoide X |
EP3704106B1 (de) | 2017-11-01 | 2023-04-12 | Bristol-Myers Squibb Company | Alken-verbindungen als farnesoid-x-rezeptormodulatoren |
JP7223016B2 (ja) | 2017-11-01 | 2023-02-15 | ブリストル-マイヤーズ スクイブ カンパニー | ファルネソイドx受容体モジュレーターとしてのアルケンスピロ環化合物 |
WO2019118571A1 (en) | 2017-12-12 | 2019-06-20 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as fxr agonists and methods of use thereof |
CN110128432B (zh) | 2018-02-02 | 2021-03-02 | 广东东阳光药业有限公司 | 含氮三环化合物及其在药物中的应用 |
WO2019160813A1 (en) | 2018-02-14 | 2019-08-22 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
EP3768690A4 (de) | 2018-03-22 | 2021-11-24 | Viking Therapeutics, Inc. | Kristalline formen und verfahren zur herstellung kristalliner formen einer verbindung |
IT201800007265A1 (it) * | 2018-07-17 | 2020-01-17 | Isossazoli come agonisti del recettore fxr | |
AU2020209564B2 (en) | 2019-01-15 | 2022-12-01 | Gilead Sciences, Inc. | FXR (NR1H4) modulating compounds |
CA3233305A1 (en) | 2019-02-19 | 2020-08-27 | Gilead Sciences, Inc. | Solid forms of fxr agonists |
US11555032B2 (en) | 2019-05-13 | 2023-01-17 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
SG11202113155XA (en) | 2019-05-30 | 2021-12-30 | Intercept Pharmaceuticals Inc | Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease |
AU2020312735A1 (en) | 2019-07-18 | 2021-12-16 | Enyo Pharma | Method for decreasing adverse-effects of interferon |
CN112824394A (zh) * | 2019-11-21 | 2021-05-21 | 中国科学院上海药物研究所 | PPARs-FXR多靶点小分子激动剂及其制备方法和用途 |
AU2021207253A1 (en) | 2020-01-15 | 2022-06-09 | Centre National De La Recherche Scientifique | Use of FXR agonists for treating an infection by hepatitis D virus |
US11478533B2 (en) | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
WO2022152770A1 (en) | 2021-01-14 | 2022-07-21 | Enyo Pharma | Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection |
WO2022229302A1 (en) | 2021-04-28 | 2022-11-03 | Enyo Pharma | Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2863874A (en) * | 1955-05-26 | 1958-12-09 | Goodrich Co B F | Process of preparing 2-aminothiazoles |
AU545463B2 (en) * | 1982-06-25 | 1985-07-18 | Kowa Co. Ltd. | Benzoyl piperacine esters |
JPS59139357A (ja) * | 1983-01-28 | 1984-08-10 | Torii Yakuhin Kk | アミジン誘導体 |
DE3621372A1 (de) * | 1986-06-26 | 1988-01-07 | Thomae Gmbh Dr K | Heterocyclisch substituierte 3,5-dihydroxy-hept-6-en-carbonsaeuren, ihre derivate, verfahren zur herstellung dieser verbindungen und die sie enthaltende arzneimittel |
DE4237768A1 (en) * | 1991-11-12 | 1993-05-13 | Ciba Geigy Ag | New polyarylene ether derivs. with reduced viscosity - used to prepare moulded bodies, foils, fibres and membranes, as matrix resins, adhesives or coating agents or as polymer additives |
DE4219247A1 (de) * | 1992-06-12 | 1993-12-16 | Bayer Ag | Verwendung von 3-arylsubstituierten 5-Alkyl-isoxazol-4-carbonsäurederivaten zur Bekämpfung von Endoparasiten, neue 3-arylsubstituierte 5-Alkyl-isoxazol-4-carbonsäurederivate und Verfahren zu ihrer Herstellung |
FR2692893B1 (fr) | 1992-06-24 | 1994-09-02 | Sanofi Elf | Dérivés alkylamino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent. |
US6005103A (en) * | 1993-11-19 | 1999-12-21 | Warner-Lambert Company | Pyrone derivatives as protease inhibitors and antiviral agents |
FR2714059B1 (fr) | 1993-12-21 | 1996-03-08 | Sanofi Elf | Dérivés amino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent. |
EP1125932A3 (de) * | 1994-07-27 | 2001-08-29 | G.D. Searle & Co. | Substituierte Thiazole zur Behandlung von Entzündungen |
EP0790057B1 (de) | 1994-11-29 | 2002-06-05 | Hisamitsu Pharmaceutical Co., Inc. | Antibakterielle oder bakterizide mittel, die 2-aminothiazolderivate und deren salze enthalten |
JP3267300B2 (ja) * | 1995-02-13 | 2002-03-18 | ジー.ディー.サール アンド カンパニー | 炎症の治療のための置換イソオキサゾール |
US5786355A (en) * | 1995-04-13 | 1998-07-28 | Taiho Pharmaceutical Co., Ltd. | 4,6-diarylpyrimidine derivatives and salts thereof |
JP4136024B2 (ja) | 1995-12-29 | 2008-08-20 | 富山化学工業株式会社 | 2−アミノチアゾ−ル誘導体またはその塩 |
US5883105A (en) | 1996-04-03 | 1999-03-16 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
JPH11263775A (ja) * | 1997-09-08 | 1999-09-28 | Sankyo Co Ltd | ヒドロキシアニリン誘導体 |
ES2255294T3 (es) * | 1998-08-07 | 2006-06-16 | Chiron Corporation | Derivados de isoxazol sustituidos como moduladores del receptor de estrogenos. |
DE69940958D1 (de) * | 1998-12-23 | 2009-07-16 | Glaxo Group Ltd | Bestimmungsmethode fur liganden der nuklearen rezeptoren |
US6201020B1 (en) * | 1998-12-31 | 2001-03-13 | Guilford Pharmaceuticals, Inc. | Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp |
CZ20013834A3 (cs) * | 1999-04-28 | 2002-04-17 | Aventis Pharma Deutschland Gmbh | Deriváty kyselin se třemi arylovými zbytky jako ligandy receptorů PPAR a farmaceutické prostředky, které je obsahují |
DE19943636A1 (de) * | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
CN100355751C (zh) * | 2000-03-29 | 2007-12-19 | 西克拉塞尔有限公司 | 2-取代的4-杂芳基-嘧啶、其组合物及其用途 |
GB0030710D0 (en) * | 2000-12-15 | 2001-01-31 | Hoffmann La Roche | Piperazine derivatives |
-
2001
- 2001-08-13 EP EP01119473A patent/EP1285914B1/de not_active Expired - Lifetime
- 2001-08-13 AT AT01119473T patent/ATE381542T1/de not_active IP Right Cessation
- 2001-08-13 DE DE60131967T patent/DE60131967D1/de not_active Expired - Lifetime
-
2002
- 2002-07-01 US US10/185,731 patent/US6974830B2/en not_active Expired - Lifetime
- 2002-07-01 US US10/185,721 patent/US7034046B2/en not_active Expired - Lifetime
- 2002-08-13 EP EP02750473A patent/EP1423111A4/de not_active Withdrawn
- 2002-08-13 US US10/217,141 patent/US7098336B2/en not_active Expired - Fee Related
- 2002-08-13 WO PCT/US2002/025436 patent/WO2003016288A1/en not_active Application Discontinuation
- 2002-08-13 WO PCT/US2002/025437 patent/WO2003015771A1/en not_active Application Discontinuation
- 2002-08-13 EP EP02750472A patent/EP1423370A4/de not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP1423370A4 (de) | 2007-04-18 |
ATE381542T1 (de) | 2008-01-15 |
EP1285914B1 (de) | 2007-12-19 |
EP1423111A4 (de) | 2007-04-18 |
WO2003015771A1 (en) | 2003-02-27 |
US7098336B2 (en) | 2006-08-29 |
US20030130296A1 (en) | 2003-07-10 |
EP1423370A1 (de) | 2004-06-02 |
US6974830B2 (en) | 2005-12-13 |
US20030149087A1 (en) | 2003-08-07 |
US7034046B2 (en) | 2006-04-25 |
EP1423111A1 (de) | 2004-06-02 |
EP1285914A1 (de) | 2003-02-26 |
US20030187042A1 (en) | 2003-10-02 |
WO2003016288A1 (en) | 2003-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60131967D1 (de) | Nr1h4-kern-rezeptor-bindende verbindungen | |
DE60231341D1 (de) | Fluor- und sulfonylaminohaltige, 3,6-disubstituierptorantagonisten | |
ATE396186T1 (de) | Heteroarylsubstituierte tetrazolmodulatoren des metabotropischen glutamatrezeptors-5 | |
MXPA03011484A (es) | Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades. | |
EA200500342A1 (ru) | Гетероциклические замещённые пиперазины для лечения шизофрении | |
BG108650A (en) | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease | |
SE0303180D0 (sv) | Novel compounds | |
SE0302232D0 (sv) | Novel Compounds | |
NO20063275L (no) | Anvendelse av substituerte 2-aminotetraliner for forebyggende behandling av Parkinsons sykdom | |
NO20062644L (no) | DPP-IV inhibitorer | |
EA200601266A1 (ru) | Соединения триазола и их применение в качестве антагонистов метаботропного рецептора глутамата | |
BR0116379A (pt) | Antagonistas de receptor y5 de neuropeptìdeo y de uréia de heteroarila | |
MEP45308A (en) | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | |
ATE466860T1 (de) | Cgrp-rezeptorantagonisten | |
SE0202838D0 (sv) | Chemical compounds | |
WO2002060900A8 (en) | Antagonists of mcp-1 function and methods of use thereof | |
DE60237528D1 (de) | Neue aminoazetidin-, aminopyrrolidin- und aminopiperidinderivative | |
EA200300716A1 (ru) | Гетероциклилалкилиндольные или -азаиндольные соединения в качестве лиганд 5-гидрокситриптамина-6 | |
SE0301368D0 (sv) | Chemical compounds | |
NO20050270L (no) | Nye forbindelser, deres anvendelse og fremstilling | |
EA200400454A1 (ru) | Мускариновые агонисты | |
EA200501593A1 (ru) | Азабициклические производные в качестве антагонистов мускаринового рецептора | |
DE60226906D1 (de) | 3,6-disubstituierte azabicyclo ä3.1.0ühexanderivate, die sich als muscarinrezeptorantagonisten eignen | |
DE60221813D1 (de) | Thiazolopyrimidinderivate und deren verwendung als antagonisten des cx3cr1 rezeptors | |
DE60225195D1 (de) | Flavaxat-derivate als muscarin-rezeptor antagonisten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8332 | No legal effect for de |